Taylor S A, Blumenstein B A, Stephens R L, Crawford E D, Pistone B, Hill J B
University of Kansas Medical Center, Kansas City.
Invest New Drugs. 1994;12(1):67-70. doi: 10.1007/BF00873240.
Menogaril, a semisynthetic anthracycline antibiotic, was administered to patients with metastatic adenocarcinoma of the prostate. Forty-five patients with measurable disease and 45 patients with evaluable disease received 150-200 mg/m2 over 1 hour every 28 days. There were three partial responses (PR) among 87 patients evaluable for response. Myelosuppression was dose limiting. There were two deaths related to leukepenia. Other toxicities included phlebitis, alopecia, nausea and vomiting. One patient developed acute nonlymphocytic leukemia. Menogaril at these doses and schedule is toxic and has no significant antitumor activity in metastatic adenocarcinoma of the prostate.
美诺加里尔是一种半合成蒽环类抗生素，曾用于治疗前列腺转移性腺癌患者。45例可测量疾病患者和45例可评估疾病患者每28天接受一次剂量为150 - 200mg/m²、持续1小时的治疗。在87例可评估反应的患者中有3例部分缓解（PR）。骨髓抑制是剂量限制性的。有2例死亡与白细胞减少有关。其他毒性包括静脉炎、脱发、恶心和呕吐。1例患者发生急性非淋巴细胞白血病。按照这些剂量和疗程使用美诺加里尔有毒性，且对前列腺转移性腺癌无显著抗肿瘤活性。
